Kelli M. Wilson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kelli M. Wilson has a total of 444 co-authors. Here are the top co-authors by number of shared publications:
- Craig J. Thomas
National Institutes of Health
170 shared publications - Carleen Klumpp-Thomas
National Center for Advancing Translational Sciences
160 shared publications - Michele Ceribelli
National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, 20850, USA
152 shared publications - Xiaohu Zhang
Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, Maryland
133 shared publications - Fathi Elloumi
Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland
96 shared publications - Yves Pommier
National Cancer Institute 2 Bethesda, Md
96 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Induced pluripotent stem cell–derived models of malignant nerve sheath tumor progression mimic glial to neuro-mesenchymal transition and uncover therapeutic opportunities
Neurofibromatosis Type 1 (NF1) predisposes to peripheral nerve tumor development. The progression from a benign plexiform neurofibroma (PNF) towards a deadly malignant peripheral nerve sheath tumor (MPNST) is not completely understood but commonly involves the sequential loss of NF1, CDKN2A, and polycomb repressive complex 2 (PRC2). Here we use an iPSC-derived neural crest (NC) model to reproduce this malignant transformation through gene editing. NF1-CDKN2A double-knockout (2KO) NCs form neurofibroma-like tumors in vivo, requiring inactivation of p14ARF and p16INK4a. Additional PRC2 loss (3KO) disrupts pluripotency and induces mesenchymal stem cell-like features. 3KO NCs undergo global chromatin reorganization that prevents gliogenesis by SOX10 silencing and activates neuro-mesenchymal transcriptional programs recapitulating PNF-ANNUBP-MPNST progression. Upon nerve engraftment, 3KO NC spheres form MPNST-like tumors in vivo, mimicking an early-stage MPNST. Furthermore, we use the 3D NC spheroid models to discover drugs targeting MPNSTs through high-throughput screening of epigenetic compounds. Poly(ADP-ribose) polymerase inhibitors (PARPi) exhibit selective efficacy in PRC2-deficient NC spheroids and Olaparib-Selumetinib combination is well tolerated and significantly suppresses tumor growth in a human MPNST PDX mouse model.
- 17 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessInduced pluripotent stem cell–derived models of malignant nerve sheath tumor progression mimic glial to neuro-mesenchymal transition and uncover therapeutic opportunities
Neurofibromatosis Type 1 (NF1) predisposes to peripheral nerve tumor development. The progression from a benign plexiform neurofibroma (PNF) towards a deadly malignant peripheral nerve sheath tumor (MPNST) is not completely understood but commonly involves the sequential loss of NF1, CDKN2A, and polycomb repressive complex 2 (PRC2). Here we use an iPSC-derived neural crest (NC) model to reproduce this malignant transformation through gene editing. NF1-CDKN2A double-knockout (2KO) NCs form neurofibroma-like tumors in vivo, requiring inactivation of p14ARF and p16INK4a. Additional PRC2 loss (3KO) disrupts pluripotency and induces mesenchymal stem cell-like features. 3KO NCs undergo global chromatin reorganization that prevents gliogenesis by SOX10 silencing and activates neuro-mesenchymal transcriptional programs recapitulating PNF-ANNUBP-MPNST progression. Upon nerve engraftment, 3KO NC spheres form MPNST-like tumors in vivo, mimicking an early-stage MPNST. Furthermore, we use the 3D NC spheroid models to discover drugs targeting MPNSTs through high-throughput screening of epigenetic compounds. Poly(ADP-ribose) polymerase inhibitors (PARPi) exhibit selective efficacy in PRC2-deficient NC spheroids and Olaparib-Selumetinib combination is well tolerated and significantly suppresses tumor growth in a human MPNST PDX mouse model.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S1 from Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Supplemental Figure S1: Effect of NAMPT inhibition and evaluation of NAD+ producing enzymes in a panel of molecularly diverse RMS cell lines and models
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S1 from Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Supplemental Figure S1: Effect of NAMPT inhibition and evaluation of NAD+ producing enzymes in a panel of molecularly diverse RMS cell lines and models
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S6 from Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Supplemental Figure S6: Gene set enrichment analysis (GSEA) comparing RMS cell lines that undergo a non-necrotic response to OT-82 versus a necrotic response to OT-82
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S6 from Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Supplemental Figure S6: Gene set enrichment analysis (GSEA) comparing RMS cell lines that undergo a non-necrotic response to OT-82 versus a necrotic response to OT-82
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S3 from Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Supplemental Figure S3: Effects of OT-82 on RMS energy metabolism
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S3 from Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Supplemental Figure S3: Effects of OT-82 on RMS energy metabolism
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table S2 from Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Supplemental Table S2: Dose range testing and IC50 parameters for OT-82 in RMS cell lines
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S2 from Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Supplemental Table S2: Dose range testing and IC50 parameters for OT-82 in RMS cell lines
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S2 from Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Supplemental Figure S2: Endpoint tumor volumes and mouse weights for in vivo experiments using OT-82 in RMS models
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S2 from Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Supplemental Figure S2: Endpoint tumor volumes and mouse weights for in vivo experiments using OT-82 in RMS models
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S4 from Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Supplemental Figure S4: Effect of OT-82 on mechanism of RMS cell death
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S4 from Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Supplemental Figure S4: Effect of OT-82 on mechanism of RMS cell death
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table S1 from Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Supplemental Table S1: Molecular features of RMS cell lines
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S1 from Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Supplemental Table S1: Molecular features of RMS cell lines
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S5 from Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Supplemental Figure S5: Mouse weights during OT-82 retreatment
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S5 from Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Supplemental Figure S5: Mouse weights during OT-82 retreatment